EMEA-002760-PIP01-19
Key facts
| Invented name |
Rubraca
|
| Active substance |
rucaparib camsylate
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0242/2020
|
| PIP number |
EMEA-002760-PIP01-19
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Clovis Oncology Ireland Ltd
E-mail: regulatoryUK@clovisoncology.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|